Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539669 | 0.87 | MAP4K1 (0.41) | MAP4K1AKT1 | |
| SCHEMBL5534996 | 0.86 | GSK3B (0.48) | KITDYRK1ACDK2DYRK1BMAP3K11 | |
| SCHEMBL5537040 | 0.85 | GSK3B (0.49) | CDK2MAP3K11 | |
| SCHEMBL5542634 | 0.83 | PRMT5 (0.45) | DYRK1ADYRK1BMAP4K1MAPK1AKT1 | |
| SCHEMBL5536743 | 0.81 | GSK3B (0.46) | DYRK1ACDK2MAP3K11LCKMAPK1 | |
| SCHEMBL5539202 | 0.80 | KIT (0.46) | KITCCNT1CCNA2CDK2CDK9 | |
| SCHEMBL5530500 | 0.77 | GRIN1 (0.39) | KITDYRK1AMAPK1AKT1 | |
| SCHEMBL5537386 | 0.77 | AXL (0.45) | — | |
| SCHEMBL29930898 | 0.77 | DYRK1A (0.65) | KITDYRK1ADYRK1BAAK1 | |
| SCHEMBL5533779 | 0.76 | DYRK1B (0.43) | DYRK1ADYRK1BMAPK1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | claimed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1545515-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | Sugen, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004014368-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | SUGEN, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | KIT 546/4885DYRK1A 516/4885CCNT1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.